Evidence map›Paper›PMID 29433504›Full record

ArticlePediatric rheumatology online journal2018

Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing - treatment protocol and preliminary results.

Lea Höfel, Bruno Eppler, Magdalena Storf, Elizabeth Schnöbel-Müller, Johannes-Peter Haas, Boris Hügle

Abstract read
In one paragraph

Article in Pediatric rheumatology online journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Evaluation of Methotrexate Intolerance in Children With Morphea.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023
    Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lea HöfelGerman Center for Pediatric and Adolescent Rheumatology (DZKJR), Gehfeldstrasse 24, 82467, Garmisch-Partenkirchen, Germany.
Bruno EpplerGerman Center for Pediatric and Adolescent Rheumatology (DZKJR), Gehfeldstrasse 24, 82467, Garmisch-Partenkirchen, Germany.
Magdalena StorfGerman Center for Pediatric and Adolescent Rheumatology (DZKJR), Gehfeldstrasse 24, 82467, Garmisch-Partenkirchen, Germany.
Elizabeth Schnöbel-MüllerCenter for Pain Treatment in Young People, Garmisch-Partenkirchen, Germany.
Johannes-Peter HaasGerman Center for Pediatric and Adolescent Rheumatology (DZKJR), Gehfeldstrasse 24, 82467, Garmisch-Partenkirchen, Germany.
Boris HügleGerman Center for Pediatric and Adolescent Rheumatology (DZKJR), Gehfeldstrasse 24, 82467, Garmisch-Partenkirchen, Germany. huegle.boris@rheuma-kinderklinik.de.ORCID http://orcid.org/0000-0003-1145-6719

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethotrexate (MTX), commonly used in juvenile idiopathic arthritis (JIA), frequently has to be discontinued due to intolerance with anticipatory and associative gastrointestinal adverse effects. Eye Movement Desensitization and Reprocessing (EMDR) is a psychological method where dysfunctional experiences and memories are reprocessed by recall combined with bilateral eye movements. The objective of this study was to assess efficacy of EMDR for treatment of MTX intolerance in JIA patients.

methodsWe performed an open prospective study on consecutive JIA patients with MTX intolerance. Intolerance was determined using the Methotrexate Intolerance Severity Score (MISS) questionnaire prior to treatment, directly after treatment and after four months. Health-related quality of life was determined using the PedsQL prior to and four months after treatment. Patients were treated according to an institutional EMDR protocol with 8 sessions over two weeks. Changes in MISS and PedsQL were analyzed using non-parametric statistics.

resultsEighteen patients with MTX intolerance (median MISS at inclusion 16.5, IQR = 11.75-20.25) were included. Directly after treatment, MTX intolerance symptoms were significantly improved (median MISS 1 (IQR = 0-2). After four months, median MISS score was at 6.5 (IQR = 2.75-12.25, p = 0.001), with 9/18 patients showing MISS scores ≥6. Median PedsQL after 4 months improved significantly from 77.6% to 85.3% (p = 0.008).

conclusionMTX intolerance in children with JIA was effectively treated using an EMDR protocol, with lasting effect over a period of 4 months. EMDR treatment can potentially increase quality of life of affected patients and enable continued MTX treatment.

Indexed as

AdolescentAntirheumatic AgentsArthritis, JuvenileChildClinical ProtocolsDesensitization, PsychologicDrug-Related Side Effects and Adverse ReactionsEye MovementsFemaleHumansMaleMethotrexateProspective StudiesQuality of LifeSeverity of Illness IndexSurveys and QuestionnairesAntirheumatic AgentsMethotrexateAdverse effectsEMDRIntoleranceJuvenile idiopathic arthritisMethotrexate

Identifiers

PMID29433504
PMCPMC5809965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.